BRIEF-CSL And Lilly Enter Licensing Agreement For Clazakizumab

-0.15%

+0.03%

Eli Lilly and Company

LLY

999.84

-0.15%

Carlisle Companies Incorporated

CSL

352.99

+0.03%

Feb 18 (Reuters) - CSL Ltd CSL.AX:

CSL AND LILLY ENTER LICENSING AGREEMENT FOR CLAZAKIZUMAB
EXCLUSIVE LICENSING AGREEMENT GRANTING CERTAIN RIGHTS TO DEVELOP AND COMMERCIALISE CLAZAKIZUMAB
CSL WILL RECEIVE AN UPFRONT PAYMENT OF $100 MILLION
CSL WILL RETAIN EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALISE CLAZAKIZUMAB FOR PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH END-STAGE KIDNEY DISEASE

Further company coverage: CSL.AX

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.